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OBJECTIVE — To evaluate the effect of adding pharmacists to primary care teams on the
management of hypertension and other cardiovascular risk factors in patients with type 2
diabetes.
RESEARCHDESIGNANDMETHODS — Weconductedarandomizedcontrolledtrial
with blinded ascertainment of outcomes within primary care clinics in Edmonton, Canada.
Pharmacists performed medication assessments and limited history and physical examinations
and provided guideline-concordant recommendations to optimize medication management.
Follow-up contact was completed as necessary. Control patients received usual care. The pri-
mary outcome was a 10% decrease in systolic blood pressure at 1 year.
RESULTS — A total of 260 patients were enrolled, 57% were women, the mean age was 59
years, diabetes duration was 6 years, and blood pressure was 129/74 mmHg. Forty-eight of 131
(37%)interventionpatientsand30of129(23%)controlpatientsachievedtheprimaryoutcome
(odds ratio 1.9 [95% CI 1.1–3.3]; P  0.02). Among 153 patients with inadequately controlled
hypertension at baseline, intervention patients (n  82) were signiﬁcantly more likely than
controlpatients(n71)toachievetheprimaryoutcome(41[50%]vs.20[28%];2.6[1.3–5.0];
P0.007)andrecommendedbloodpressuretargets(44[54%]vs.21[30%];2.8[1.4–5.4];P
0.003). The 10-year risk of cardiovascular disease, based on changes to the UK Prospective
Diabetes Study Risk Engine, were predicted to decrease by 3% for intervention patients and 1%
for control patients (P  0.005).
CONCLUSIONS — Signiﬁcantly more patients with type 2 diabetes achieved better blood
pressure control when pharmacists were added to primary care teams, which suggests that
pharmacists can make important contributions to the primary care of these patients.
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T
ype 2 diabetic patients are predis-
posed to a clustering of cardiovas-
cular risk factors, including
hypertension and dyslipidemia (1). Car-
diovascular disease is the leading cause of
death and disability in these patients and
contributestoasubstantialincreaseinan-
nual per capita management costs (2,3).
Although the link between glycemic con-
trol and the reduction of myocardial in-
farctionorstrokeriskintype2diabetesis
somewhat tenuous, it is the usual focus of
diabetesmanagementinprimarycareset-
tings.Conversely,thereisstrongevidence
demonstrating that management of hy-
pertension and dyslipidemia in these pa-
tients signiﬁcantly lowers the risk of both
microvascular and cardiovascular com-
plications (4). Indeed, blood pressure re-
duction probably has a greater impact on
cardiovascular disease than improved
glycemiccontrol,yetitisoftenconsidered
a secondary priority (5–7).
With the heightened risk of cardio-
vascular disease in type 2 diabetes, ag-
gressive cardiovascular risk-factor
management is recommended (8). How-
ever, uptake of these recommendations is
less than ideal. For example, in northern
Alberta, Canada, only 10% of all type 2
diabeticpatientssimultaneouslyachieved
guideline-recommended treatment tar-
gets for A1C, blood pressure, and choles-
terol (9). These ﬁndings are consistent
withobservationsfromelsewhereinCan-
ada, the U.S., and the European Union,
where5%ofdiabeticpatientsmetthese
combined treatment targets. Possible ex-
planations for the discrepancy between
evidence-based recommendations and
currentpracticeincludeaglucocentricfo-
cus of diabetes care and the complex
medication regimens often required to
achieve treatment targets. For instance,
two or more antihypertensive medica-
tions may be required to achieve blood
pressure targets (10).
Pharmacists are trained to optimize
medicationmanagement,especiallywhen
regimens become complex. Addition of
pharmacists to in-patient services and
specialty clinics can improve outcomes
and lower total medical costs. However,
studies of pharmacist contributions to di-
abetes management have focused on gly-
cemic control (11). We identiﬁed only
three randomized controlled trials that
examined pharmacist contributions to
type 2 diabetes management and that
used improvements in blood pressure
control as the primary outcome (supple-
mentary Table 1 and supplementary Fig. 1
in the online appendix, available at http://
care.diabetesjournals.org/cgi/content/full/
dc10-1294/DC1) (12–14). Although all
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difﬁcult to generalize the ﬁndings to pri-
marycaresettings.Onestudy(12)wasset
in a university-afﬁliated clinic where
pharmacists had prescriptive authority
and direct contact with university-based
specialist physicians. The other two stud-
ies (13,14) were set in community phar-
macies where pharmacists indirectly
communicated recommendations to pri-
mary care physicians via fax or letter.
These previous studies did not examine
the effects of pharmacists working di-
rectly with a primary care team.
For these reasons, we studied the ef-
fect of adding pharmacists to extant mul-
tidisciplinary primary care teams (the
Canadian equivalent of the patient-
centered medical home [15]) on cardio-
vascularrisk-factormanagementintype2
diabetes.Wefocusedonhypertensionbe-
cause it is the most common risk factor
present in type 2 diabetic patients, and
any insights garnered could be easily ap-
plied to other primary care patients with
hypertension. We hypothesized that
compared with usual care, the addition of
a pharmacist would signiﬁcantly change
blood pressure control.
RESEARCH DESIGN AND
METHODS— This randomized con-
trolledtrialwasconductedinﬁveprimary
care clinics afﬁliated with the Edmonton
South Side Primary Care Network in Ed-
monton, Canada. These primary care
teams were akin to the patient-centered
medical home (15) and consisted of phy-
sicians and nurses who had support from
dietitians, physiotherapists, and social
workers as needed. Patients were eligible
if they had type 2 diabetes, were regularly
seen by the primary care team, and did
not qualify for urgent specialist referral
and assessment (according to protocol, a
fasting blood glucose 17 mmol/l, blood
pressure 220/120 mmHg, or triglycer-
ides 15 mmol/l). We excluded patients
who were followed in specialty clinics for
diabetes, hypertension, or dyslipidemia;
whowerecognitivelyimpaired;whowere
not responsible for their own medication
administration; or who were unable to
communicate in English. Blood pressure
screening was not conducted during pa-
tientrecruitmenttominimizecontamina-
tion of controls. Because type 2 diabetic
patientshavehigherbloodpressurelevels
than the general population (1), we felt
that this approach was justiﬁable for a
pragmatic study design.
Eligible patients were identiﬁed from
theclinicroster,andaclinicstaffmember
made initial contact to tell patients about
the study. Patients were told that the
studywasdesignedtohelpimprovemed-
ication therapy for heart disease risk in
patientswithtype2diabetes.Thespeciﬁc
focus of the study, hypertension, was
listed among other risk factors for heart
disease. The University of Alberta Health
ResearchEthicsBoardapprovedthestudy
protocol,andallparticipantsgavewritten
informed consent. Pharmacists were
given access to the patient’s clinical chart
after consent to participate in the study
was obtained.
Randomization
A central randomization service (www.
epicore.ualberta.ca) provided computer-
generated random sequences stratiﬁed by
the primary care clinic for treatment allo-
cation. Pharmacists, analysts, and investi-
gators were unaware of the block size and
allocation sequence to preserve allocation
concealment.
Control patients
Control patients received usual care by
the primary care team without contribu-
tions from study pharmacists, except for
standardized blood pressure measure-
ments at the end of the follow-up period
(see below).
Intervention
Two pharmacists providing the interven-
tion program held a Bachelor’s Degree in
pharmacy, were Certiﬁed Diabetes Edu-
cators, and had practiced in community
pharmacies for over 5 years. Both phar-
macists completed structured online
training courses for hypertension and di-
abetes management (www.pharmalearn.
com) and reviewed the Canadian
Hypertension Education Program and
Canadian Diabetes Association guideline
recommendations prior to starting the
study (16,17).
Theinterventionprogrambeganwith
anin-personvisitwithastudypharmacist
to identify all prescription, nonprescrip-
tion, complementary, and alternative
medications. Pharmacists also measured
the patient’s height, weight, heart rate,
and blood pressure. Blood pressure was
measured according to the Canadian Hy-
pertension Education Program recom-
mendations using the BPTru BPM-100
(VSM Med Tech, Coquitlam, BC) auto-
matedmachinesettoreporttheaverageof
ﬁve measurements at 1-min intervals
(16). Pharmacists then formulated guide-
line-concordant recommendations to op-
timize medication management of blood
pressure and other cardiovascular risk
factors. These recommendations were
discussedwiththeprimarycarephysician
who was responsible for authorizing
medicationchanges.Thepharmacistthen
workedindependentlywiththepatientto
implement these changes.
Follow-up
Baseline characteristics were obtained
fromtheclinicchart.Interimcontactwith
intervention patients was made at the dis-
cretion of the pharmacist, physician, or
patient and could be conducted via tele-
phoneorinperson.Interimcontactswere
used to determine whether medication
changes were implemented and to ad-
dressquestionsorconcernssincethepre-
viousencounter(e.g.,sideeffects,adverse
events, or adherence issues). Pharmacists
recordedthedate,duration,andnatureof
each contact with a study patient. After 1
year, all patients were seen in the primary
care clinic to review medications, mea-
sure blood pressure with the automated
machine, and obtain a fasting blood sam-
ple to measure blood glucose, A1C, and
cholesterol proﬁle. Patients also reported
the number of encounters with special-
ists, other health care professionals, re-
gional health care resources, emergency-
room visits, and hospitalizations during
the previous year.
Outcomes
Theprimaryoutcomewasachievementof
a clinically important reduction in blood
pressure, deﬁned as a 10% decrease in
systolicbloodpressureat1year(18).Sec-
ondary outcomes included the absolute
change in systolic blood pressure from
baseline to 1 year, achievement of recom-
mendedbloodpressuretargets(130/80
mmHg) (8), and antihypertensive medi-
cation changes. We also measured the
change in predicted 10-year risk of car-
diovasculardiseaseusingtheUKProspec-
tive Diabetes Study (UKPDS) Risk Engine
(19). Baseline and follow-up values for
A1C,systolicbloodpressure,totalcholes-
terol, and HDL cholesterol were used to
calculate the change in the UKPDS Risk
Engine score.
Statistical analysis
Our sample size was based on observa-
tions from a previous study (20) examin-
ing the effect of a diabetes intervention
program aimed at physicians. In that
study, 40% of intervention patients and
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decrease in blood pressure at 6 months.
Althoughthecurrentstudyfollow-upwas
twice as long and the intervention was di-
rected at patients, we estimated that the
event rates would be similar. With a two-
sided  of 0.05 and 80% power, we esti-
mated the total sample size would be
300 patients.
We used 
2 statistics to test for be-
tween-group differences in the primary
outcome. The association between treat-
ment group and achievement of the pri-
mary outcome was also examined using a
logistic regression model to calculate an
odds ratio (OR) and 95% CI. The unit of
analysis and causal inference was the pa-
tient. Based on the results of related trials
inourregion(13,20,21),weassumedthat
patient-related outcomes were statisti-
cally independent of one another, with
intracluster correlation coefﬁcients
0.01. All patients were evaluated in the
groups to which they were randomly al-
located according to the intention-to-
treat principle. Missing data were
replaced by carrying the last observation
forward.
To test the robustness of our observa-
tions, we restricted our analyses to pa-
tients who completed the full study
protocol and patients with inadequately
controlled hypertension at baseline. We
also conducted two sensitivity analyses to
account for potential hierarchical statisti-
cal clustering. First, we used indicator
variables to directly adjust for all 18 fam-
ily physicians involved in the study in a
multivariate logistic regression model.
Second, we used generalized estimating
equation methodology to account for the
potential correlations of outcomes among
patients treated by the same physician.
None of the sensitivity analyses changed
the direction, magnitude, or statistical
signiﬁcance of our ﬁndings; therefore, we
report only our prespeciﬁed analyses. A P
value of 0.05 was considered statisti-
cally signiﬁcant, and PASW Statistics ver-
sion18.0(SPSS,Chicago,IL)wasusedfor
all analyses.
RESULTS— We enrolled 260 patients
between 28 February 2006 and 6 Decem-
ber 2007 and randomly allocated 131 to
the intervention and 129 to the control
group (Fig. 1). The main reasons for ex-
clusion were that the pharmacist could
notcontacteligiblepatients(700of1,183
[59%]) and patient refusal (211 of 1,183
[18%]). The ﬁnal 1-year follow-up visit
was completed on 30 January 2009.
There were 21 intervention patients (14
withdrew, 6 were lost to follow-up, and 1
died) and 16 control patients (10 with-
drew and 6 were lost to follow-up) who
did not complete the study (P  0.05 for
all comparisons). There were no differ-
ences in age, sex, diabetes duration, or
baseline blood pressure between the pa-
tients who did or did not complete the
study.
Figure 1—Study participant ﬂowchart. ICD-9, International Classiﬁcation of Diseases, 9th revision; BP, blood pressure; ITT, intention to treat.
Blood pressure control in diabetes
22 DIABETES CARE, VOLUME 34, NUMBER 1, JANUARY 2011 care.diabetesjournals.orgPatient characteristics
Baseline characteristics were well bal-
anced between the groups (Table 1).
There were 149 (57.3%) women, mean
(SD) age was 59.1  11.6 years, BMI
was 32.5  6.5 kg/m
2, diabetes duration
was 5.5  6.5 years, and A1C was 7.4 
1.4%. The mean blood pressure at base-
line was 129.4  15.3/74.1  10.4
mmHg, with 82 of 131 (63%) interven-
tion patients and 71 of 129 (55%) control
patients having inadequately controlled
hypertension(130/80mmHg;P0.22
for difference). Of 107 patients with a
blood pressure 130/80 mmHg, 76 were
taking one or more antihypertensive
medications at baseline.
Blood pressure changes
Over 1 year, there was a statistically sig-
niﬁcant reduction in systolic blood pres-
sure for intervention patients (mean
decrease 7.4 mmHg [95% CI 4.6–10.2];
P  0.001) but not for control patients
(2.5 mmHg [0.1 to 5.2]; P  0.06)
(supplementary Fig. 1). The between-
group difference in systolic blood pres-
sure change at 1 year was 4.9 mmHg
(95%CI1.0–8.7;P0.01)(supplemen-
tary Table 2) in favor of the intervention.
Theprimaryoutcomewasachievedby48
of131(37%)interventionpatientsand30
of 129 (23%) control patients (OR 1.91
[95% CI 1.11–3.28]; P  0.02) (Fig. 2).
The absolute difference of 14% translates
to a number needed to treat (NNT) of
seven patients followed for 1 year by a
pharmacist to achieve one additional pa-
tient with better blood pressure control
compared with usual care.
Limiting our analyses to 223 patients
whocompletedthestudyrevealedsimilar
results. The mean decrease in systolic
blood pressure was 7.7 mmHg (95% CI
4.5–10.9;P0.001)forinterventionpa-
tients and 2.8 mmHg (0.2 to 5.8; P 
0.07) for control patients (P  0.03 for
between-group differences). More inter-
vention patients achieved the primary
outcome (41 of 110 [37%]) compared
with control patients (30 of 113 [27%]);
however, this difference was not statisti-
cally signiﬁcant (P  0.09).
We observed a larger treatment effect
whenbloodpressurechangeswereexam-
ined in 153 patients with inadequately
controlledhypertensionatbaseline.Mean
blood pressure at baseline was 138.7 
11.4/78.8  9.4 mmHg for intervention
patients and 137.9  14.1/78.1  11.4
mmHgforcontrolpatients(P0.05).All
other baseline characteristics for these
153 patients were well balanced between
the two groups (P  0.05 for all compar-
isons). Systolic blood pressure decreased
a mean of 13.9 mmHg (95% CI 10.6–
17.1;P0.001)forinterventionpatients
and 6.7 mmHg (3.2–10.1; P  0.001) for
control patients (P  0.002 for between-
group differences) (supplementary Fig.
1).Theprimaryoutcomewasachievedby
41 of 82 (50%) intervention patients and
20 of 71 (28%) control patients (OR 2.55
[95% CI 1.30–5.01]; P  0.007) (Fig. 2).
This absolute difference of 22% translates
toanNNTofﬁve.Moreover,amongthese
153patients,44of82(54%)intervention
patients and 21 of 71 (30%) control pa-
tients achieved recommended blood
pressure targets at 1 year (2.76 [ 1.41–
5.39]; P  0.003; NNT  4).
Antihypertensive medication
changes
Fifty-ﬁve(42%)interventionpatientshad
85changesand32(25%)controlpatients
had 44 changes to their antihypertensive
medication regimen (OR 2.19 [95% CI
1.30–3.71]; P  0.003) (supplementary
Fig. 2). Among those with uncontrolled
hypertension at baseline, only 61 of 153
(40%) had changes. The most common
antihypertensive medications added to a
patient’s regimen were ramipril (10 pa-
tients), hydrochlorothiazide (9 patients),
and irbesartan (8 patients).
Other outcomes
Although changes in glycemic control
and lipid parameters all favored the inter-
vention, other than blood pressure con-
trol, none achieved statistical signiﬁcance
(supplementary Table 2). Using the
UKPDS Risk Engine (19), there was a sta-
tistically signiﬁcant reduction in pre-
dicted 10-year risk of cardiovascular
eventsforinterventionpatients(meande-
crease 2.7% [95% CI 1.5–3.9 ]; P 
0.001) but not for control patients (1.2%
[0.1 to 2.4 ]; P  0.06). The between-
group difference was 1.5% (95% CI 0.2
to 3.3; P  0.005) in favor of the inter-
vention (supplementary Table 2).
The total number of health care–
related contacts was 1,439 for interven-
tion patients and 420 for control patients
(P0.01;supplementaryTable3).How-
ever, 1,442 (77.6%) of these contacts
were either protocol driven (baseline and
1-year follow-up) visits or interim con-
tacts between intervention patients and
study pharmacists. Two-thirds of the in-
terim contacts were conducted over the
telephone. There were no differences in
Table 1—Baseline characteristics
Characteristic
Control
patients
Intervention
patients
n 129 131
Age (years) 59.4  12.1 58.8  11.1
Female 75 (58.1) 74 (56.5)
Current smoker 15 (11.6) 19 (14.5)
BMI (kg/m
2) 33.4  5.7 31.8  7.0
Comorbidities
Atrial ﬁbrillation 10 (7.8) 4 (3.1)
Coronary artery disease 23 (17.8) 18 (13.7)
Stroke 3 (2.3) 7 (5.3)
Peripheral arterial disease 5 (3.9) 2 (1.5)
Depression 21 (16.3) 31 (23.7)
Duration of diabetes (years) 5.9  7.8 5.0  4.9
A1C (%) 7.3  1.3 7.5  1.6
Cholesterol (mmol/l)
Total 4.37  0.98 4.41  0.96
LDL 2.41  0.72 2.42  0.80
HDL 1.15  0.31 1.15  0.25
Triglycerides 1.74  0.87 1.90  1.13
Blood pressure (mmHg)
Systolic 128.3  15.7 130.4  14.9
Diastolic 73.9  10.8 74.4  10.0
Uncontrolled (130/80 mmHg) 71 (55.0) 82 (62.6)
UKPDS Risk Engine score (19) (%) 21.0  19.5 19.5  16.4
Data are means  SD for continuous variables and n (%) for categorical variables.
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[8.5%]), hospitalizations (4 [3.1%] vs.
ﬁve [3.9%]), or all-cause mortality (1
[0.8%] vs. 0 [0%]) between groups dur-
ing the study.
CONCLUSIONS — To our knowl-
edge, this is the largest randomized con-
trolled trial reporting the effect of adding
pharmacists to primary care teams on
blood pressure control in type 2 diabetic
patients. On average, most patients were
relativelywellcontrolledintermsofA1C,
blood pressure, and other cardiovascular
riskfactors;areﬂectionofboththequality
of usual care in this primary care network
andthefactthatstudyparticipantstendto
be “healthier” than nonparticipants. Nev-
ertheless, adding pharmacists to primary
care teams resulted in more intervention
patients achieving a clinically important
reduction in systolic blood pressure at 1
year compared with control patients. The
absolutedifferenceof14%translatestoan
NNT of seven, and absolute beneﬁts were
even greater among those who had inad-
equately controlled hypertension (i.e.,
22% improvement, NNT of ﬁve). Glyce-
mic control, cholesterol management,
and predicted 10-year risk of cardiovas-
cular disease all showed a trend toward
improvement with the pharmacist
intervention.
A 10% reduction in systolic blood
pressure is considered clinically worth-
while, (18) and, if sustained for another 4
years,wouldbeassociatedwithan25%
reduction in cardiovascular events (22).
Our observations are broadly consistent
with three previous studies (12–14) that
examinedpharmacistcontributionstodi-
abetic hypertension management. All
three studies reported a signiﬁcant differ-
enceinsystolicbloodpressurechangebe-
tween groups and favored pharmacist
intervention (supplementary Fig. 1). In
our study, we might have seen a greater
difference in systolic blood pressure
change between groups if we had ex-
cluded people with normal blood pres-
sureorwell-controlledhypertension(n
107 [41%]) or included those with ele-
vated hypertension (220/120 mmHg).
We believe that the success of this
study can be attributed to three critical
components of the pharmacist interven-
tion.First,pharmacistsusedguidelinesto
help formulate medication management
recommendations. These evidence-based
resources provided a validated, external
benchmark to identify treatment options.
Second, pharmacists discussed their rec-
ommendationsdirectlywithprimarycare
physicians and other health care profes-
sionals, which is considered an essential
component of successful management
programs (23). Anecdotally, these in-
person “hallway” discussions facilitated a
richer exchange of patient-speciﬁc ideas
compared with more impersonal e-mails
or faxes that are commonly used by phar-
macists in the community. Third, the fre-
quency of follow-up contact was tailored
tothepatient’sneeds.Wehavefoundthat
the effects of an intervention decay over
time without direct, continuous involve-
ment and individualized support of clini-
cians (20,21,24).
Limitations
There are a number of limitations to con-
sider when interpreting our results. First,
we examined relatively short-term
changes in surrogate measures rather
than harder longer-term clinical end
points such as myocardial infarction,
stroke, or death. This limitation may be
Figure 2—Proportion of patients achieving a 10% decrease in systolic blood pressure at 1 year (primary outcome).
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changesintheUKPDSriskscoreobserved
with the intervention.
Second, there was the possibility of
“contamination” or “cointervention” be-
cause both intervention and control pa-
tients were drawn from the same primary
careteam.Althoughweconsideredaclus-
ter-randomized trial, we estimated that
therewerenotenoughprimarycareteams
to carry out such a study. Contamination
would only tend to bias to the null, and
without the pharmacist’s active interven-
tion it is unlikely that the primary care
team would pay greater attention than
usual to blood pressure control in those
with diabetes.
Third, our 14% drop-out rate was
high but consistent with other random-
ized controlled trials of pharmacist in-
volvement in diabetic hypertension
management (11–14). Withdrawal rates
were similar between groups, and there
were no signiﬁcantly different character-
istics between patients who withdrew or
completed the study.
Fourth, our intervention was con-
ducted in a jurisdiction with universal
health care coverage and set within estab-
lished primary care teams or patient-
centered medical homes, so usual care
was already much better than reported in
the previous literature. Nonetheless,
therewasstillroomforimprovement,and
adding pharmacists to this team did im-
prove care. It is likely, therefore, that the
intervention would have an even greater
effect when implemented in settings with
a lower baseline quality of care.
Last, the multifaceted nature of our
intervention program makes it difﬁcult to
attribute the observed differences to a
speciﬁc component. We believe the next
stage in this line of research could be an
activecomparatorstudyexaminingtheef-
fects of pharmacists, perhaps with pre-
scriptive autonomy, relative to other case
managers.
Conclusion
Our observations support the addition of
pharmacists to primary care teams.
Working in collaboration with the pa-
tient, primary care physician, and other
healthcareprofessionals,pharmacistscan
have a signiﬁcant, positive impact on
blood pressure management in type 2 di-
abetes. We believe our results are appli-
cable to a broad range of patients with
type 2 diabetes managed in primary care
settings and can be extended to nondia-
betic patients with inadequately con-
trolled hypertension.
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